Dr. Rekha Pal is a highly accomplished cancer biologist specializing in immuno-oncology, translational research, and the tumor microenvironment. With extensive experience across both discovery and clinical development, she has led programs for targeted therapies and immune checkpoint inhibitors, including pivotal work on the molecular targets of thalidomide derivatives like pomalidomide and lenalidomide. Dr. Pal excels at bridging the gap between bench and clinic by developing complex cell-based disease models—such as organoids and primary human cell cultures—and collaborating with computational biologists to correlate genomic signatures with drug interactions for biomarker selection. Her multifaceted expertise at Crown Bioscience encompasses the design of in vitro and in vivo studies, the establishment of clinical protocols for patient sample analysis, and the successful navigation of IRB and IACUC regulatory frameworks to accelerate drug development programs.